Chris O’Brien Lifehouse
Hospital
Location:
Sydney,
Australia (AU)
ISNI: -
ROR: https://ror.org/00qeks103
Show on Map:
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R (2024)
Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, et al.
Journal article
Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial (2023)
Koch R, Haveman L, Ladenstein R, Brichard B, Jürgens H, Cyprova S, van den Berg H, et al.
Journal article
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma (2022)
Koch R, Gelderblom H, Haveman L, Brichard B, Jürgens H, Cyprova S, Van Den Berg H, et al.
Journal article
PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2021)
Girard N, Smit HJM, Sibille A, Mcdonald F, Mornex F, Garassino MCC, Filippi AR, et al.
Conference contribution